您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > CD532
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CD532
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CD532图片
规格:98%
分子量:522.5
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
CD532 是一种有效的 Aurora A 激酶抑制剂,IC50 为 45 nM。 CD532 具有阻断 Aurora A 激酶活性和驱动 MYCN 降解的双重作用。 CD532 还可以直接与 AURKA 相互作用并诱导全局构象转变。 CD532可用于癌症的研究。
货号:ajcx24950
CAS:1639009-81-6
分子式:C26H25F3N8O
分子量:522.5
溶解度:Ethanol: soluble
纯度:98%
存储:Store at -20°C
库存:现货

Background:

CD532 is an inhibitor of Aurora A kinase activity (IC50= 48 nM) and the protein-protein interaction between N-Myc and Aurora A kinase.1It also inhibits several cyclin-dependent kinases (CDKs), FGFRs, MEKs, and PDGFRs, as well as FLT3, KIT, and RET at 10 µM.2CD532 induces degradation of N-Myc in SK-N-BE(2) neuroblastoma cells (EC50= 223 nM).1It prevents S-phase entry in SK-N-BE(2) cells when used at a concentration of 1 µM.1CD532 (25 mg/kg) reduces tumor growth and increases survival in aMYCN-amplified SMS-KCN neuroblastoma mouse xenograft model.


1.Gustafson, W.C., Meyerowitz, J.G., Nekritz, E.A., et al.Drugging MYCN through an allosteric transition in Aurora kinase ACancer Cell26(3)414-427(2014) 2.Lee, J.K., Phillips, J.W., Smith, B.A., et al.N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cellsCancer Cell29(4)536-547(2016)